Relative carcinogenicity of tacrolimus vs mycophenolate after solid organ transplantation and its implications for liver transplant care

Table 1 Inclusion and exclusion criteria utilised for literature search strategy

Inclusion criteria	Exclusion criteria
Involve human solid organ transplant recipients	Presents risk data on only one of the immunosuppressant medications
Independent malignancy risk analysis related to both immunosuppressants mycophenolic acid and tacrolimus	Does not specify type of immunosuppression
Contains a group of participants exposed to tacrolimus or mycophenolic acid, exclusive of the other	Mean follow up less than one year (given the slow growing nature of malignancy)
Greater than 100 participants	Not published in English
Greater than 5 cases of malignancy	Full text not available
Randomised controlled trials and observational studies	Systematic reviews and meta-analyses